A17-peptide

A17 peptide is a Hsp70-targeting peptide. A17 peptide binds to the ATP-binding domains of Hsp70. A17 peptide specifically inhibits the chaperone activity, thereby increasing the cells' sensitivity to apoptosis induced by chemotherapeutic agents, such as Cisplatin. A17 peptide can be used for anticancer chemotherapy research, such multiple myeloma[1].

1140483-31-3

12352209

HSP

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Cancer

O=C(N[C@@H](CS)C(N[C@@H](C)C(N[C@@H](CC1=CC=C(C=C1)O)C(N[C@@H](CC2=CC=C(C=C2)O)C(N[C@@H](CO)C(N3[C@@H](CCC3)C(N[C@@H](CCCNC(N)=N)C(N[C@@H](CC4=CNC=N4)C(N[C@@H](CCCCN)C(N[C@@H]([C@H](O)C)C(N[C@@H]([C@H](O)C)C(N[C@@H](CC5=CC=CC=C5)C(O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)=O)[C@H](CC6=CC=C(C=C6)O)N

C76H105N19O20S

1636.83

[1]Rérole AL, et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. Cancer Res. 2011 Jan 15;71 (2) :484-95.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-P11053/

Peptides

No Development Reported

HSP70